0001136261-22-000155.txt : 20220304 0001136261-22-000155.hdr.sgml : 20220304 20220304160213 ACCESSION NUMBER: 0001136261-22-000155 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220228 FILED AS OF DATE: 20220304 DATE AS OF CHANGE: 20220304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Golembiewski Michael Joseph CENTRAL INDEX KEY: 0001639479 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22245 FILM NUMBER: 22713981 MAIL ADDRESS: STREET 1: 7 TURTLE CT CITY: FLEMINGTON STATE: NJ ZIP: 08822 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 293-2100 MAIL ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 4 1 ownership.xml X0306 4 2022-02-28 0 0001017491 SEELOS THERAPEUTICS, INC. SEEL 0001639479 Golembiewski Michael Joseph C/O SEELOS THERAPEUTICS, INC. 300 PARK AVENUE, 2ND FLOOR NEW YORK NY 10022 0 1 0 0 Chief Financial Officer Common Stock 2022-02-28 5 A 0 E 12500 0.901 A 78487 D These shares were acquired under the Company's 2020 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). /s/ Michael Golembiewski 2022-03-04